In a sign that it is still struggling as competition emerges for it major drugs Procrit and Risperdal and that its stent business is still troubled by safety concerns, Johnson & Johnson (JNJ) announced that it would buy back as much as $10 billion of its shares.
JNJ has a market cap of $186 billion. The announcement did not move the shares much. They inched up 1.5% to $63, and are down about 6% this year.
With 2006 revenue of $53 billion, its is a bit surprising that JNJ is not using the capital to buy another company. It is hard not to imagine that it pharma business could not benefit from the R&D at one or more of its smaller biotech partners.
But, it’s only $10 billion.
Douglas A. McIntyre
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
